# Evolent Health, Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Evolent Health, Inc.](/companies/evh.md) (CIK 1628908)
- Form: 10-Q
- Filed: 2021-11-04
- Accepted by EDGAR: Nov 3, 2021, 18:24 ET
- Period: 2021-09-30
- Accession: 0001628908-21-000149
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000149/evh-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1628908/000162890821000149/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Selling, general and administrative | 3 months, 2021-07-01 to 2021-09-30 | $51.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-01-01 to 2021-09-30 | $152.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$6.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$30.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-07-01 to 2021-09-30 | $6.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-01-01 to 2021-09-30 | $19.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | $234.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $936.0k | us-gaap:IncomeTaxExpenseBenefit |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.37 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$0.37 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 85,800,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 85,306,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$27.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-09-30 | $252.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $478.2m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $1.25bn | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $367.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $646.0m | us-gaap:Liabilities |
| Long-term debt | at 2021-09-30 | $211.1m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-09-30 | $26.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-09-30 | $607.5m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 75,908 characters.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to help the reader understand the Company’s financial condition and results of operations. The MD&A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in “Part I – Item 1. Financial Statements” of this Form 10-Q; our 2020 Form 10-K, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; and our current reports on Form 8-K filed in 2021.

### INTRODUCTION

### Background

Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

### Business Overview

We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models. We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology.

We were an early innovator in Value-Based Care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company.

Today we manage our operations and allocate resources across two reportable segments: Clinical Solutions and Evolent Health Services. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.

The Company’s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management.

All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.

We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. We also expect to continue to incur operating losses for the foreseeable future and if we are unable to achieve our revenue growth and cost management objectives, we may not be able to achieve profitability.

As of the date the financial statements were available to be issued, we believe we have sufficient liquidity for the next 12 months.

### Recent Events

### Evolent Health’s Response to COVID-19

On March 11, 2020, the World Health Organization (the “WHO”) declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. While response to the COVID-19 outbreak, including the emergence of variant strains of the virus, continues to rapidly evolve, it has led to aggressive actions to reduce the spread of the disease that seriously disrupted activities in large segments of the economy. We are continuing to monitor the COVID-19 outbreak and its impact on our business.

Because of the nature of the services we provide, market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition or results of operations or our outlook. As of September 30, 2021, we had cash and cash equivalents of $252.5 million and as of the date the financial statements were available to be issued we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. The COVID-19 crisis has also affected global access to capital and caused significant volatility in financial markets. Significant deterioration of the U.S. and global economies could have a significant adverse impact on our future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.

Evolent’s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish high quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer, and Chief Talent Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities. Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors, and we will continue to work with them regarding our collective obligations to Evolent’s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner.

#### Summary of Impact of COVID-19

In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In evaluating our health plan partners, we focused on possible changes in membership and medical utilization trends.

Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services. Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.

The three key end-markets we serve are Medicaid, Medicare and Commercial.

Across 2020 and into the first nine months of 2021, we saw changes in membership and medical utilization in our end-markets as a result of the COVID-19 pandemic. The pandemic resulted in a significant increase in unemployment in the United States. Historically, Medicaid enrollment has increased during periods of rising unemployment as individuals lose access to employer sponsored health care and turn to government sponsored health care. In addition, with respect to Medicaid, many states (including Florida, Kentucky and Illinois) put in place new rules during the pandemic eliminating the ability of Medicaid health plans to dis-enroll non-paying members, as well as waiving certain eligibility requirements, which together contributed to an increase in membership during the period of the pandemic. In aggregate, as more than 50% of our lives on platform as of September 30, 2021, are in Medicaid and we generally earn revenue with respect to those lives based on a per member per month model, we have experienced a modest net benefit in our business from increased membership in that market in the near-term. We cannot predict the magnitude of this potential benefit, or how long it will last.

With respect to medical utilization, following the declaration of the pandemic by the WHO, many state-wide mandates deferred non-essential medical procedures to allow hospitals to focus on providing care to COVID-19 patients. Across all markets, our partners experienced declines in non-essential care throughout the year ended December 31, 2020 and through the first nine months of 2021, offset in part by increased costs for care of COVID-19 patients. We continue to monitor medical utilization trends closely as the pandemic progresses. Beginning late in the first quarter of 2020 after declaration of the pandemic and continuing through the first nine months of 2021, we have seen a modest benefit in our business from lower utilization trends. However, we cannot predict with any certainty the net impact of lower utilization on our business, as it is possible we will experience a surge in utilization as consumer behavior changes (for example if the novel coronavirus is controlled by the available vaccines or other measures).

Overall, we are unable to determine or predict the nature, duration, or scope of the overall impact the COVID-19 pandemic will have on our business, results of operations, liquidity, or capital resources. We are actively monitoring the ongoing situation and may take further actions that change our operations if required by law or that we determine are in the best interests of our employees or partners.

### Customers

The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2021 and 2020:

|  | For the Three Months Ended September 30, 2021 | 2020 (1) | For the Nine Months Ended September 30, 2021 | 2020 (1) |
| --- | ---: | ---: | ---: | ---: |
| Cook County Health and Hospitals Systems | 29.0% | 23.1% | 29.0% | 22.0% |
| Florida Blue Medicare, Inc. | 13.8% | \* | 14.2% | \* |
| Passport | \* | 22.9% | \* | 25.0% |

(1) The denominator excludes $29.5 million and $87.1 million of True Health premium revenue reclassified to discontinued operations for the three and nine months ended September 30, 2020, respectively.

\* Represents less than 10.0% of the respective balance.

Cook County Health and Hospital Systems utilizes both our administrative simplification solutions provided by Evolent Health Services, which accounted for 9.2% of our consolidated revenue for both the three and nine months ended September 30, 2021 and our specialty care management solutions provided by New Century Health which accounted for 19.8% of our consolidated revenue for both the three and nine months ended September 30, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.

### Transactions

The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.

#### Acquisition of Vital Decision

On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, entered into a definitive agreement for Evolent to acquire Windrose Health Investors III, L.P. portfolio company Vital Decisions for $85 million, with an additional earn out of up to $45 million. Vital Decisions will report into Evolent’s specialty care management offering, New Century Health, and will be consolidated into the Company’s Clinical Solutions segment. The transaction closed on October 1, 2021.

#### Sale of True Health New Mexico

On January 11, 2021, Evolent LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into the SPA with Bright HealthCare, pursuant to which EH Holdings agreed to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of $22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the True Health Closing based in part on actual medical claims experience. The True Health Closing occurred on March 31, 2021 and the Company has had no continuing involvement with True Health subsequent to the Closing except a pre-existing services agreement for claims processing and other health plan administrative functions. Refer to “Part I - Item 1. Financial Statements - Note 5” for additional discussion regarding the True Health sale.

In addition, in conjunction with the sale of True Health, the Company made organizational changes, including re-evaluating its reportable segments. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company’s Evolent Health Services segment (“EHS”) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to “Part I - Item 1. Financial Statements - Note 21 for a further discussion of our operating results by segment.

#### Passport

On December 30, 2019, UHC, Passport Health Solutions, LLC (“PHS I”), the Company and EVH Passport, closed a transaction whereby EVH Passport acquired substantially all of the assets and assumed substantially all of the liabilities of UHC, including the

Passport Medicaid Contract. The purchase price paid by EVH Passport consisted of $70.0 million in cash and a 30% equity interest in EVH Passport issued to the Sponsors; however, $16.2 million of the foregoing cash purchase price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements.

On September 1, 2020, EVH Passport and Molina completed the Molina Closing and the Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited $20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting. As a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company’s consolidated financials, EVH Passport redeemed the Sponsors’ equity interests in EVH Passport in accordance with the terms of EVH Passport's Stockholders' Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company. The Company expects a return of capital from EVH Passport, expected to be between $130 million and $170 million in total, which is subject to regulatory approval from the Kentucky Department of Insurance. Refer to “Part I - Item 1. Financial Statements - Note 4” for additional discussion regarding the Passport transactions.

#### Repayment and Termination of Existing Credit Agreement

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Corporation under the Credit Agreement in connection with the prepayment was $98.6 million, which included $9.7 million for the make-whole premium as well as $0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for $13.7 million. Refer to “Part I - Item 1. Financial Statements - Note 10” for additional discussion relating to the repayment of the Credit Agreement.

### Repositioning Plan

We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.

In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (“Repositioning Plan”). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives. The Repositioning Plan is expected to conclude in the fourth quarter of 2021.

The following table provides a summary of our total costs associated with the Repositioning Plan for the three and nine months ended September 30, 2021, by major type of cost (in thousands):

|  | Incurred For the Three Months Ended September 30, 2021 | Incurred for the Nine Months Ended September 30, 2021 | Total Amount Expected to be Incurred in the Repositioning Plan | Cumulative Amount Incurred through September 30, 2021 |
| --- | ---: | ---: | ---: | ---: |
| Severance and termination benefits | $— | $185 | $185 | $185 |
| Office space consolidation | — | 2,071 | 2,321 | 2,071 |
| Professional services | — | 3,787 | 5,562 | 5,062 |
| Total | $— | $6,043 | $8,068 | $7,318 |

### Critical Accounting Policies and Estimates

The “Management Discussion and Analysis” included in our 2020 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2020 Form 10-

K. See “Item 1. Financial Statements - Note 2” in this Form 10-Q for a summary of our significant accounting policies and see “Item 1. Financial Statements - Note 3” in this Form 10-Q for information regarding the Company’s adoption of new accounting standards.

### Summary of Significant Accounting Policies

Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See “Part II - Item 8. Financial Statements and Supplementary Data - Note 2” in our 2020 Form 10-K for a complete summary of our significant accounting policies.

#### Goodwill

We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.

Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit’s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).

We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three and nine months ended September 30, 2021. We will perform our annual impairment test as of October 31, 2021.

A description of our 2020 goodwill impairment test follows below.

The Company performed an interim goodwill impairment assessment in one of our three reporting units in the EHS segment as of March 31, 2020 due to the decline in the Company’s stock price during the first quarter of 2020 and lack of excess of fair value over the carrying value considering the $199.8 million impairment charge taken in the fourth quarter of 2019. The Company concluded that the fair value of its reporting unit was more than its carrying value as of March 31, 2020. In addition, the Company performed an interim goodwill impairment assessment as of May 31, 2020 and concluded that the fair value of one of our three reporting units in the EHS segment was less than its carrying value by $215.1 million as of May 31, 2020. The decrease in fair value was due to our largest customer, EVH Passport, not obtaining a renewal of its Kentucky managed Medicaid contract, which was its sole business. The non-renewal of EVH Passport’s contract caused a reduction in the Company’s cash flow projections.

As a result of the impairment charges in the fourth quarter of 2019 and second quarter of 2020, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for the specific reporting unit that incurred those impairment charges. This election does not preclude Management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required.

In performing our October 31, 2020 impairment test for one of the specific reporting unit reference above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (“income approach”). In determining the estimated fair value using the income approach, we projected future cash flows based on management’s estimates and long-term plans and applied a discount rate based on the Company’s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.

As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting units was less than the reporting unit’s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. As of December 31, 2020, the remaining goodwill attributable to the reporting unit from which we recognized a non-cash goodwill impairment charge earlier in the year was $214.3 million.

### Adoption of New Accounting Standards

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments* and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, customer advances and certain off-balance sheet credit exposures, by replacing the existing “incurred loss” framework with an expected credit loss recognition model. The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts. The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based on specific identification. Under the new accounting standard, we utilize several factors to develop historical losses, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach. Refer to Note 7 for additional disclosures related to current expected credit losses.

In December 2019, the FASB issued ASU No. 2019-12, *Simplifying the Accounting for Income Taxes*. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.

### RESULTS OF OPERATIONS

Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.

### Key Components of our Results of Operations

#### Revenue

We derive revenue primarily from transformation services and platform and operations services.

Transformation Services Revenue

Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.

Platform and Operations Services Revenue

Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.

Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time.

In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope.

Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.

Contracts with Multiple Performance Obligations

Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.

In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.

#### Cost of Revenue (exclusive of depreciation and amortization)

Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements. Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the runout of EVH Passport’s operations, consisting principally of updates to EVH Passport’s claims reserve based on actual claims payments.

#### Selling, General and Administrative Expenses

Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.

#### Depreciation and amortization expense

Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC’s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.

#### Lives on Platform and PMPM Fees

Evolent Health Services lives on platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions lives on platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Technology and Services suite lives on platform are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts under ASO arrangements. Members covered for more than one category are counted in each category.

Evolent Health Services Average per member per month (“PMPM”) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment in the period divided by the average of the beginning and ending Evolent Health Services segment membership during the quarter divided by the number of months in the period. Clinical Solutions Performance suite PMPM fee is defined as platform and operations services revenue pertaining to our Performance suite in the period divided by the average of the beginning and ending Performance suite membership for the relevant divided by the number of months in the period. New Century Technology and Services suite PMPM fee is defined as platform and operations revenue pertaining to the New Century Technology and Services suite in the period divided by the average of the beginning and ending New Century Technology and Services suite membership for the relevant period divided by the number of months in the period.

Management uses lives on platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

### Evolent Health, Inc. Consolidated Results

*(in thousands, except percentages)*

| 2021 Revenue | For the Three Months Ended September 30, 2020 |  | Change Over Prior Period $% | 2021 | For the Nine Months Ended September 30, 2020 |  | Change Over Prior Period $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Transformation services | $2,075 | $4,807 | $(2,732) | (56.8)% | $4,984 | $10,800 | $(5,816) | (53.9)% |
| Platform and operations services | 220,396 | 234,765 | (14,369) | (6.1)% | 654,615 | 667,303 | (12,688) | (1.9)% |
| Total revenue | 222,471 | 239,572 | (17,101) | (7.1)% | 659,599 | 678,103 | (18,504) | (2.7)% |
| **Expenses** |  |  |  |  |  |  |  |  |
| Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) | 163,126 | 181,761 | (18,635) | (10.3)% | 493,071 | 521,748 | (28,677) | (5.5)% |
| Selling, general and administrative expenses | 51,292 | 52,366 | (1,074) | (2.1)% | 152,582 | 151,749 | 833 | 0.5% |
| Depreciation and amortization expenses | 14,859 | 14,534 | 325 | 2.2% | 44,962 | 46,130 | (1,168) | (2.5)% |
| Loss on extinguishment of debt, net | — | 4,789 | (4,789) | (100.0)% | — | 4,789 | (4,789) | (100.0)% |
| Loss on disposal of assets and consolidation | — | — | — | —% | — | 6,447 | (6,447) | (100.0)% |
| Goodwill impairment | — | — | — | —% | — | 215,100 | (215,100) | (100.0)% |
| Change in fair value of contingent consideration and indemnification asset | (225) | 2,570 | (2,795) | (108.8)% | (819) | (492) | (327) | (66.5)% |
| Total operating expenses | 229,052 | 256,020 | (26,968) | (10.5)% | 689,796 | 945,471 | (255,675) | (27.0)% |
| Operating loss | $(6,581) | $(16,448) | $9,867 | 60.0% | $(30,197) | $(267,368) | $237,171 | 88.7% |
| Transformation services revenue as a % of total revenue | 0.9% | 2.0% |  |  | 0.8% | 1.6% |  |  |
| Platform and operations services revenue as a % of total revenue | 99.1% | 98.0% |  |  | 99.2% | 98.4% |  |  |
| Cost of revenue as a % of revenue | 73.3% | 75.9% |  |  | 74.8% | 76.9% |  |  |
| Selling, general and administrative expenses as a % of total revenue | 23.1% | 21.9% |  |  | 23.1% | 22.4% |  |  |

### Comparison of the Results for the Three Months Ended September 30, 2021 to 2020

#### Revenue

Total revenue decreased by $17.1 million, or 7.1%, to $222.5 million for the three months ended September 30, 2021, as compared to 2020.

Transformation services revenue decreased by $2.7 million, or 56.8%, to $2.1 million for the three months ended September 30, 2021, as compared to 2020, due primarily to the timing and volume of implementation activities. Transformation services revenue accounted for 0.9% and 2.0% of our total revenue for the three months ended September 30, 2021 and 2020, respectively.

Platform and operations services revenue decreased by $14.4 million, or 6.1%, to $220.4 million for the three months ended September 30, 2021, as compared to 2020. We expect our platform and operations growth rate in 2021 to increase as a result of the impact of new customer additions, offset, in part by the wind-down of EVH Passport’s operations compared to 2020. Platform and operations services revenue accounted for 99.1% and 98.0% of our total revenue for the three months ended September 30, 2021 and 2020, respectively.

The following table represents Evolent’s revenue disaggregated by segment and end-market for the three months ended September 30, 2021 and 2020 (in thousands):

|  | For the Three Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Medicaid | $41,857 | $51,637 | $51,829 | $73,480 |
| Medicare | 4,816 | 28,483 | 91,249 | 63,663 |
| Commercial and other | 30,154 | 19,830 | 2,566 | 2,479 |
| Total | $76,827 | $99,950 | $145,644 | $139,622 |

Revenue from our Evolent Health Services segment decreased by $23.1 million for the three months ended September 30, 2021 as compared to 2020 due to the runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $6.0 million for the three months ended September 30, 2021 as compared to 2020 due to new partner additions as well as expansion into new markets within current New Century Technology and Services Suite partners.

The following table represents the Company’s lives on platform as of September 30, 2021 and PMPM fees for the three months ended September 30, 2021 and 2020 (lives on platform in thousands):

|  | Lives on Platform September 30, 2021 | 2020 | Average PMPM Fees For the Three Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Evolent Health Services | 1,564 | 1,841 | $13.19 | $17.64 |
| Clinical Solutions |  |  |  |  |
| Performance suite | 1,471 | 1,611 | $34.16 | $29.92 |
| New Century Technology and Services suite | 11,670 | 4,946 | $0.36 | $0.41 |

We had 41 and 34 operating partners as of September 30, 2021 and 2020, respectively.

#### Cost of Revenue

The following table provides a summary of our total cost of revenue by segment for the three months ended September 30, 2021, as compared to 2020 (amounts in thousands):

|  | For the Three Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 | 2021 Corporate | 2020 | 2021 Total | 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $42,651 | $44,007 | $119,894 | $130,558 | $581 | $7,196 | $163,126 | $181,761 |

Cost of revenue decreased by $18.6 million, or (10.3)%, to $163.1 million for the three months ended September 30, 2021, as compared to 2020. Cost of revenue decreased by approximately $13.1 million period over period as a result of lower capitation expenses and $3.1 million in our personnel costs due to a lower headcount. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for three months ended September 30, 2021 includes approximately $2.7 million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport’s claims reserve. Approximately $0.1 million and $0.4 million of total personnel costs was attributable to stock-based compensation expense for the three months ended September 30, 2021 and 2020, respectively. Cost of revenue represented 73.3% and 75.9% of total services revenue for the three months ended September 30, 2021 and 2020, respectively. Our cost of revenue decreased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to continue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.

#### Selling, General and Administrative Expenses

The following table provides a summary of our selling, general and administrative expenses by segment for the three months ended September 30, 2021, as compared to 2020 (amounts in thousands):

|  | For the Three Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 | 2021 Corporate | 2020 | 2021 Total | 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $26,826 | $18,589 | $4,314 | $4,630 | $20,152 | $29,147 | $51,292 | $52,366 |

Selling, general, and administrative expenses decreased by $1.1 million, or 2.1%, to $51.3 million for the three months ended September 30, 2021, as compared to 2020. Selling, general, and administrative expenses decreased approximately $4.1 million period over period due to termination of leases at Passport, legal expense decreased $1.0 million due to the timing and volume of transactions. These were offset, in part by, stock compensation increases of $1.5 million due primarily to restricted stock awards to employees and professional fees of $1.4 million primarily due to the Repositioning Plan and shareholder advisory services. Approximately $4.3 million and $2.7 million of total personnel costs were attributable to stock-based compensation expense for the three months ended September 30, 2021 and 2020, respectively. Acquisition and severance costs accounted for approximately $1.2 million and $2.6 million of total selling, general and administrative expenses for the three months ended September 30, 2021 and 2020, respectively. Selling, general and administrative expenses represented 23.1% and 21.9% of total revenue for the three months ended September 30, 2021, as compared to 2020, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the fourth quarter of 2020.

#### Depreciation and Amortization Expenses

Depreciation and amortization expenses increased $0.3 million, or 2.2%, to $14.9 million for the three months ended September 30, 2021, as compared to 2020. The increase was due primarily to higher amortization of internal-use software, offset, in part by, a decrease in amortization expense for existing technology intangibles. We expect depreciation and amortization expenses to continue to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.

#### Loss on extinguishment of debt, net

In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment to noteholders of $2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations.

#### Change in Fair Value of Contingent Consideration and Indemnification Asset

We recorded a gain (loss) on change in fair value of contingent consideration and indemnification asset of $(0.2) million and $2.6 million for the three months ended September 30, 2021 and 2020, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018, 2019 and 2020.

### Comparison of the Results for the Nine Months Ended September 30, 2021 to 2020

#### Revenue

Total revenue decreased by $18.5 million, or 2.7%, to $659.6 million for the nine months ended September 30, 2021, as compared to 2020.

Transformation services revenue decreased by $5.8 million, or 53.9%, to $5.0 million for the nine months ended September 30, 2021, as compared to 2020, due primarily to the timing and volume of implementation activities. Transformation services revenue accounted for 0.8% and 1.6% of our total revenue for the nine months ended September 30, 2021 and 2020, respectively.

Platform and operations services revenue decreased by $12.7 million, or 1.9%, to $654.6 million for the nine months ended September 30, 2021, as compared to 2020. This decrease is primarily due to the consolidation and wind-down of EVH Passport’s operations compared to 2020. We expect our platform and operations growth rate in 2021 to increase as a result of the impact of new customer additions, including Florida Blue Medicare, Inc. Platform and operations services revenue accounted for 99.2% and 98.4% of our total revenue for the nine months ended September 30, 2021 and 2020, respectively.

The following table represents Evolent’s revenue disaggregated by segment and end-market for the nine months ended September 30, 2021 and 2020 (in thousands):

|  | For the Nine Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Medicaid | $154,850 | $165,584 | $148,816 | $197,992 |
| Medicare | 19,500 | 57,729 | 267,793 | 190,223 |
| Commercial and other | 62,177 | 59,535 | 6,463 | 7,040 |
| Total | $236,527 | $282,848 | $423,072 | $395,255 |

Revenue from our Evolent Health Services segment decreased by $46.3 million for the nine months ended September 30, 2021 as compared to 2020 due to the runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $27.8 million for the nine months ended September 30, 2021 as compared to 2020 due to new partner additions including Florida Blue Medicare, Inc., as well as expansion into new markets within current New Century Technology and Services Suite partners.

The following table represents the Company’s lives on platform as of September 30, 2021 and PMPM fees for the nine months ended September 30, 2021 and 2020 (Lives on Platform in thousands):

|  | Lives on Platform September 30, 2021 | 2020 | Average PMPM Fees For the Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Evolent Health Services | 1,564 | 1,841 | $12.23 | $14.56 |
| Clinical Solutions |  |  |  |  |
| Performance suite | 1,471 | 1,611 | 28.78 | 29.83 |
| New Century Technology and Services suite | 11,670 | 4,946 | 0.38 | 0.41 |

We had 41 and 34 operating partners as of September 30, 2021 and 2020, respectively.

#### Cost of Revenue

The following table provides a summary of our total cost of revenue by segment for the nine months ended September 30, 2021, as compared to 2020 (amounts in thousands):

|  | For the Nine Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 | 2021 Corporate | 2020 | 2021 Total | 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $145,354 | $163,386 | $345,874 | $347,980 | $1,843 | $10,382 | $493,071 | $521,748 |

Cost of revenue decreased by $28.7 million, or 5.5%, to $493.1 million for the nine months ended September 30, 2021, as compared to 2020. Cost of revenue decreased by approximately $21.0 million due to lower personnel costs, $4.4 million in lower professional fees and $3.3 million in our technology services, TPA fees, brokerage fees and other costs. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for the nine months ended September 30, 2021 includes approximately $8.5 million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport’s claims reserve. Approximately $1.6 million and $1.4 million of total personnel costs was attributable to stock-based compensation expense for the nine months ended September 30, 2021 and 2020, respectively. Cost of revenue represented 74.8% and 76.9% of total services revenue for the nine months ended September 30, 2021 and 2020, respectively. Our cost of revenue decreased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.

#### Selling, General and Administrative Expenses

The following table provides a summary of our total selling, general and administrative by segment for the nine months ended September 30, 2021, as compared to 2020 (amounts in thousands):

|  | For the Nine Months Ended September 30, 2021 Evolent Health Services | 2020 | 2021 Clinical Solutions | 2020 | 2021 Corporate | 2020 | 2021 Total | 2020 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Total | $69,555 | $68,736 | $21,086 | $16,272 | $61,941 | $66,741 | $152,582 | $151,749 |

Selling, general, and administrative expenses increased by $0.8 million, or 0.5%, to $152.6 million for the nine months ended September 30, 2021, as compared to 2020. Professional fees increased by $11.2 million for the nine months ended September 30, 2021, as compared to 2020, respectively, primarily due to the Repositioning Plan and shareholder advisory services. During the nine months ended September 30, 2021, personnel costs decreased by $3.2 million period over period due to a reduction in employee headcount, other expenses decreased by $3.5 million due to the termination of leases at Passport during the third quarter of 2020 and legal fees decreased $3.2 million due to the timing and volume of transactions. Approximately $10.1 million and $9.0 million of total personnel costs were attributable to stock-based compensation expense for the nine months ended September 30, 2021 and 2020, respectively. Acquisition and severance costs accounted for approximately $3.3 million and $9.4 million of total selling, general and administrative expenses for the nine months ended September 30, 2021 and 2020, respectively. Selling, general and administrative expenses represented 23.1% and 22.4% of total revenue for the nine months ended September 30, 2021, as compared to 2020, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the fourth quarter of 2020.

#### Depreciation and Amortization Expenses

Depreciation and amortization expenses decreased $1.2 million, or 2.5%, to $45.0 million for the nine months ended September 30, 2021, as compared to 2020. The decrease was due primarily to lower amortization on existing technology intangibles, offset, in part by, an increase in amortization expense for internal-use software. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.

#### Loss on extinguishment of debt, net

In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment to noteholders of $2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations.

#### Gain (Loss) on Disposal of Assets and Consolidation

During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the nine months ended September 30, 2020, the Company sold its interest in the subsidiary and recorded a $6.4 million loss on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.

#### Goodwill Impairment

During the nine months ended September 30, 2020 we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the two reporting units in the EHS segment was less than the carrying amount. See “Part I - Item 1. Financial Statements - Note 9” for further details of the impairment charge to goodwill.

#### Change in Fair Value of Contingent Consideration and Indemnification Asset

We recorded a gain on change in fair value of contingent consideration and indemnification asset of $0.8 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018, 2019 and 2020.

### Discussion of Non-Operating Results

#### Interest Income

Interest income consists of interest from investing cash in money market funds and interest from both our short-term and long-term investments. We recorded interest income of $0.1 million and $0.3 million and for the three and nine months ended September 30, 2021, respectively, and $1.2 million and $2.6 million for the three and nine months ended September 30, 2020, respectively. Interest income decreased during 2021 as a result of the repayment of the $40.0 million Passport Note on November 24, 2020.

#### Interest Expense

Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and Credit Agreement with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $6.4 million and $19.0 million for the three and nine months ended September 30, 2021, respectively, and $7.4 million and $20.0 million for the three and nine months ended September 30, 2020, respectively. The decrease in interest expense is driven primarily by the termination of the Ares Credit Agreement in January 2021, offset, in part by the issuance of the 2024 Notes in August 2020. See “Part I - Item 1. Financial Statements - Note 10” in this Form 10-Q for further details.

#### Impairment of Equity Method Investments

As of June 30, 2020, the Oklahoma Insurance Division (“OID”) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we have recorded a non-cash impairment charge of approximately $47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the nine months ended September 30, 2020.

#### Gain (Loss) from Equity Method Investees

The Company allocated its proportional share of the investees’ earnings and losses each reporting period. The Company’s proportional share of the gains from its equity method investments was approximately $0.1 million and $12.7 million for the three and nine months ended September 30, 2021, respectively and $(13.7) million and $11.0 million for the three and nine months ended September 30, 2020, respectively. The change in gain from equity method investees for the three months ended September 30, 2021 compared to 2020 is driven primarily by the Company’s investment in Passport. The change in gain from equity method investees for the nine months ended September 30, 2021 compared to 2020 is driven primarily by the Company’s investment in Passport during 2020 combined with gains on the sale of our Florida equity investee’s membership during 2021.

#### Gain from Transfer of Membership

During the nine months ended September 30, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% will be receivable in the first quarter of 2022 subject to the satisfaction of certain contingencies.

#### Loss On Repayment of Debt

On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6 million, which included $9.7 million for the make-whole premium as well as $0.2 million in accrued interest.

As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2 million, representing the remaining unamortized debt issuance costs of $9.5 million, the make-whole premium and legal expenses.

#### Provision for Income Taxes

The Company recorded $0.2 million and $0.9 million in income tax expense (benefit) for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (1.8)% and (2.9)%, respectively, and $0.5 million and $(3.1) million for the three and nine months ended September 30, 2020, respectively, which resulted in effective tax rates of (1.3)% and 1.0%, respectively. The difference between our effective tax rate and our statutory rate is due primarily to the fact that the Company maintains a full valuation allowance recorded against its net deferred tax assets, with the exception of certain indefinite-lived components.

#### Loss from Discontinued Operations, Net of Tax

As of September 30, 2021, the Company determined that True Health met the held for sale criteria under ASC 360, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as held for sale and are not included in continuing operations in the consolidated financial statements. The True Health Closing occurred on March 31, 2021.

The following table summarizes the results of operations of the Company’s True Health business, which are included in the loss from discontinued operations in the consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020.

| Revenue | For the Three Months Ended September 30, 2021 | 2020 | For the Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Platform and operations | — | 71 | 38 | 350 |
| Premiums | — | 29,487 | 44,795 | 87,136 |
| Total revenue | — | 29,558 | 44,833 | 87,486 |
| **Expenses** |  |  |  |  |
| Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) (1) | — | 4,926 | 5,885 | 12,861 |
| Claims expenses | — | 21,325 | 33,954 | 63,136 |
| Selling, general and administrative expenses (2) | — | 4,407 | 5,764 | 14,318 |
| Depreciation and amortization expenses | — | 160 | 160 | 480 |
| Total operating expenses | — | 30,818 | 45,763 | 90,795 |
| Operating loss | — | (1,260) | (930) | (3,309) |
| Interest income | — | 129 | 112 | 415 |
| Interest expense | — | (3) | (4) | (10) |
| Other loss | — | (1) | (25) | (4) |
| Loss before income taxes and non-controlling interests | — | (1,135) | (847) | (2,908) |
| Benefit for income taxes | — | — | (326) | — |
| Net loss | $— | $(1,135) | $(521) | $(2,908) |

(1) Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $3.7 million for the three months ended September 30, 2020 and $2.8 million and $10.0 million for the nine months ended September 30, 2021 and 2020, respectively.

(2) Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $1.0 million of for the three months ended September 30, 2020 and $1.1 million and $5.1 million for the nine months ended September 30, 2021 and 2020, respectively.

### REVIEW OF CONSOLIDATED FINANCIAL CONDITION

### Liquidity and Capital Resources

Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $30.2 million and $267.4 million for the nine months ended September 30, 2021 and 2020, respectively. Net cash and restricted cash used in operating activities was $27.9 million and $3.4 million for the nine months ended September 30, 2021 and 2020, respectively.

As of September 30, 2021, the Company had $252.5 million of cash and cash equivalents and $29.3 million in restricted cash and restricted investments.

We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.

#### Cash Flows

The following summary of cash flows for the nine months ended September 30, 2021 and 2020 (in thousands) has been derived from our financial statements included in “Part I - Item 1. Financial Statements - Consolidated Statements of Cash Flows:”

|  | For the Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Net cash and restricted cash used in operating activities | $(27,909) | $(3,374) |
| Net cash and restricted cash provided by investing activities | 38,582 | 263,297 |
| Net cash and restricted cash provided by (used in) financing activities | (90,446) | 12,054 |

Operating Activities

Cash flows used in operating activities of $27.9 million for the nine months ended September 30, 2021 were primarily due to our net loss of $32.0 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $45.1 million and stock-based compensation expense of $11.8 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in accrued liabilities and accrued compensation and employee benefits contributed approximately $88.0 million to our cash outflows. Those cash outflows were offset, in part by increased reserves for claims and performance-based arrangements of approximately $16.8 million.

Cash flows used in operating activities of $3.4 million in the nine months ended September 30, 2020 were due primarily to our net loss of $320.4 million, partially offset by non-cash items, including an impairment of goodwill of $215.1 million, an impairment of an equity method investment of $47.1 million, depreciation and amortization expenses of $46.6 million, stock-based compensation expense of $10.4 million and a loss on the disposal of assets of $6.4 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts payable, accrued liabilities and claims reserves contributed approximately $10.6 million to our cash outflows. Those cash inflows were partially offset by an increase in accounts receivable and contract assets and contract costs assets and a decrease in accrued compensation and employee benefits contributed of approximately $28.3 million.

Investing Activities

Cash flows provided by investing activities of $38.6 million in the nine months ended September 30, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $14.2 million offset, in part by $17.7 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments.

Cash flows from investing activities of $263.3 million in the nine months ended September 30, 2020 were primarily attributable to cash flows from the impact of the initial consolidation of Passport of $159.8 million, maturities and sales of investments of $140.9 million, offset, in part by investments in internal-use software and purchases of property and equipment of $23.6 million, disposal of non-strategic assets of $2.3 million and purchases of investments of $11.2 million.

Financing Activities

Cash flows used in financing activities of $90.4 million in the nine months ended September 30, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $1.1 million decrease in net working capital balances held on behalf of our partners for claims processing services.

Cash flows from financing activities of $12.1 million in the nine months ended September 30, 2020 were primarily related to $30.1 million from proceeds of convertible debt, offset, in part by repurchase of our 2021 Notes of $16.4 million, $1.4 million of taxes withheld and paid for vests of restricted stock units and a $2.2 million decrease in working capital balances held on behalf of our partners for claims processing services. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.

#### Cash flows from Discontinued Operations

The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business, which was sold on March 31, 2021, during the nine months ended September 30, 2021 and 2020 were as follows:

|  | For the Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Cash flows provided by (used in) operating activities | $5,002 | $7,920 |
| Cash flows provided by (used in) investing activities | (2,494) | 936 |

#### Contractual Obligations

Our estimated contractual obligations (in thousands) as of September 30, 2021, were as follows:

|  | 2021 | 2022-2023 | 2024-2025 | 2026+ | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases for facilities | $2,961 | $18,626 | $16,594 | $47,760 | $85,941 |
| Purchase obligations related to vendor contracts | 3,814 | 8,380 | 123 | — | 12,317 |
| Debt interest and termination payments | 3,613 | 13,369 | 9,279 | — | 26,261 |
| Debt principal repayment (1) | 26,737 | — | 289,551 | — | 316,288 |
| Total contractual obligations | $37,125 | $40,375 | $315,547 | $47,760 | $440,807 |

(1) Debt principal repayments in 2021 includes the remaining $26.7 million of 2021 Notes. Refer to “Part I - Item 1. Financial Statements - Note 10” for additional discussion relating to the repayment of the 2021 Notes.

During the nine months ended September 30, 2021, the only material change from December 31, 2020 outside the ordinary course of business in the contractual obligations set forth above was the repayment and termination of our Credit Agreement and settlement of our warrant agreements with Ares Capital Corporation. Refer to the discussion in “Part I - Item 1. Financial Statements - Note 10” for additional information on our long-term debt.

#### Accounts Receivable, net

Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the nine months ended September 30, 2021, accounts receivable, net increased due to the impact of new customers of $60.0 million and the timing of cash receipts from existing customers.

#### Restricted Cash and Restricted Investments

Restricted cash and restricted investments of $29.3 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $13.2 million, collateral for letters of credit required as security deposits for facility leases of $3.4 million, amounts held with financial institutions for risk-sharing arrangements of $12.0 million and other restricted balances of $0.7 million as of September 30, 2021. See “Part I - Item 1. Financial Statements - Note 2” for further details of the Company’s restricted cash balances.

#### Uses of Capital

Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.

### OTHER MATTERS

#### Off-balance Sheet Arrangements

Through September 30, 2021, the Company had not entered into any off-balance sheet arrangements, other than the operating leases and notes receivable noted above, and did not have any holdings in variable interest entities, other than the unconsolidated variable interest entities discussed in “Part I - Item 1. Financial Statements - Note 16” within this Form 10-Q.

#### Related Party Transactions

In the ordinary course of business, we enter into transactions with related parties. Information regarding transactions and amounts with related parties is discussed in “Part I - Item 1. Financial Statements - Note 19” within this Form 10-Q.

#### Other Factors Affecting Our Business

In general, our business is subject to a changing social, economic, legal, legislative and regulatory environment. Although the eventual impact on us of the changing environment in which we operate remains uncertain, these factors and others could have a material effect on our results of operations, liquidity and capital resources. Factors that could cause actual results to differ materially from those set forth in this section are described in “Part I - Item 1A. Risk Factors” and “Forward-Looking Statements – Cautionary Language.”

## Market risk

As filed, 2,134 characters.

We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.

#### Interest Rate Risk

As of September 30, 2021, the Company had cash and cash equivalents and restricted cash and restricted investments of $281.8 million, which consisted of bank deposits with FDIC participating banks of $280.5 million, bank deposits in international banks of $1.3 million.

Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.

As of September 30, 2021, we had $316.3 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. Refer to the discussion in “Part I - Item 1. Financial Statements - Note 10” for additional information on our long-term debt.

#### Foreign Currency Exchange Risk

Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized foreign currency translation loss of $4 thousand and $85 thousand for the three and nine months ended September 30, 2021.

## Controls and procedures

As filed, 2,934 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of September 30, 2021 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

#### Inherent Limitations of Internal Controls

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

## Risk factors

As filed, 6,285 characters.

Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2020. These risk factors are supplemented for the item described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.

*We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with a significant partner, or multiple partners in the aggregate, could negatively impact our results.*

Historically, we have relied on a limited number of partners for a substantial portion of our total revenue and accounts receivable. Our largest partner in terms of both revenue and accounts receivable, Cook County Health and Hospitals System, comprised 29.0% of our revenue for both the three and nine months ended September 30, 2021 and 43.7% and 61.5% of our accounts receivable as of September 30, 2021 and December 31, 2020, respectively. The loss of Cook County Health and Hospitals System or any other significant partner, pursuant to a reprocurement process or otherwise, or the non-renewal or renegotiation of any of our significant partner contracts, could adversely affect our results. In May 2020, Passport, our largest partner at the time, was not awarded a Kentucky managed Medicaid contract for the next contract period, which adversely affected our results. We cannot assure you that similar facts will not occur with a different partner in the future as often our customers who are county or municipal run bodies have requirements to run public procurement processes for renewals.

In the ordinary course of business, we engage in active discussions and renegotiations, and at times we are required to participate in reprocurement or other RFP exercises with our partners in respect of the services we provide and the terms of our partner agreements, including our fees. As our partners’ businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our partners have renegotiated or terminated, or not renewed, and we expect that in the future additional partners will, from time to time, seek to renegotiate or terminate or not renew their agreements with us. These discussions and future discussions have resulted and could result in reductions to the fees and changes to the scope of services contemplated by our original partner contracts and consequently have and could negatively impact our revenues, business and prospects. In addition, we may not successfully win new contracts or renewals of existing contracts through competitive market standard reprocurement or RFP processes.

Because we rely on a limited number of partners for a significant portion of our revenues, we depend on the creditworthiness of these partners. Our partners are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our partners declines, our credit risk could increase. Should one or more of our significant partners (including Cook County) declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable and affect our bad debt reserves and net income (loss).

Although we have long-term contracts with many partners, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our partners after a notice period has passed and the partner has paid a termination fee. Certain of our contracts are terminable immediately upon the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. In addition, certain of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our partners is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health typically run for one-year terms. While they typically contain year-to-year renewal provisions, we cannot assure that any or all of these contracts will be renewed in any particular year. We expect that future contracts will contain similar provisions to those described in this paragraph.

Filed Nov 4, 2021.
Source: SEC EDGAR, the filing index for accession 0001628908-21-000149. Last ingested by Listed: Nov 15, 2026, 04:22 ET. No prices; not investment advice.
